PhoenixBio Co., Ltd. (JP:6190)
:6190
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥252.00 - ¥724.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.83B
Enterprise Value¥1.28B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)6.1
Beta0.52
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.91
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PXB-mice PlatformOwning a specialized humanized-animal platform is a durable competitive advantage: it creates high technical barriers to entry, drives recurring demand from drug developers needing liver models, and supports long-term pricing power and customer stickiness in preclinical workflows.
Diverse Revenue Streams (models, Services)Multiple revenue channels—product sales, licensing, and fee-for-service CRO work—help diversify cash sources and smooth cyclicality. Contract research relationships can produce multi-study pipelines and recurring revenues, supporting steady demand over the medium term.
Stable Balance Sheet, Moderate LeverageA healthy equity ratio and moderate leverage provide financial flexibility to fund R&D or bridge cash shortfalls without excessive refinancing risk. This stability preserves optionality for partnerships or incremental investments that support long-term commercialization.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow constrains the company's ability to self-fund R&D, capex, or scale operations. Over months, this heightens reliance on external financing, which can dilute shareholders or limit strategic flexibility if capital markets tighten.
Ongoing Negative Profitability & Declining RevenueDeclining top-line combined with negative EBITDA and net margins signals structural or execution issues in monetizing the platform. Sustained unprofitability undermines reinvestment capacity and raises risk that core services need re-pricing or cost restructuring to reach sustainable margins.
Shrinking Asset Base / Small ScaleA decreasing asset base and small headcount limit capacity to scale multiple large CRO studies simultaneously and reduce operational resilience. Long-term growth may be constrained by resource bottlenecks and reduced ability to invest in parallel platform expansion.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥252.00 and its highest was ¥724.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.83B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 47 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥19.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.91.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥19.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―